Section Arrow
AVTX.NASDAQ
- Avalo Therapeutics
Quotes are at least 15-min delayed:2026/04/10 17:25 EDT
After Hours
Last
 13.66
0 (0.00%)
Bid
13.66
Ask
13.73
High 14 
Low 13.5 
Volume 47.42K 
Regular Hours (Closed)
Last
 13.66
-0.55 (-3.87%)
Day High 
14.28 
Prev. Close
14.21 
1-M High
18.47 
Volume 
726.12K 
Bid
13.66
Ask
13.73
Day Low
13.2516 
Open
14.19 
1-M Low
13.075 
Market Cap 
323.82M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 15.2 
20-SMA 14.96 
50-SMA 15.48 
52-W High 20.7199 
52-W Low 3.39 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.84/-3.12
Enterprise Value
337.31M
Balance Sheet
Book Value Per Share
3.64
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
59.00K
Operating Revenue Per Share
0.74
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
After Hours 0.4441 -0.0578 -11.52%
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
After Hours 0.1206 -0.0157 -11.52%
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
After Hours 0.1717 +0.0676 +64.94%
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
After Hours 6.61 0 0.00%
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
After Hours 3.78 +0.08 +2.16%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipelinealso includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.